Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Collegium Pharmaceutical's 3-Year RORE % for the quarter that ended in Mar. 2026 was -9.30%.
The industry rank for Collegium Pharmaceutical's 3-Year RORE % or its related term are showing as below:
FRA:354's 3-Year RORE % is ranked worse than 57.78% of 938
companies
in the Drug Manufacturers industry
Industry Median: 3.09
vs FRA:354: -9.30
Collegium Pharmaceutical (FRA:354) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Collegium Pharmaceutical 3-Year RORE % Related Terms
Collegium Pharmaceutical 3-Year RORE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:354 vs ALVO, PAHC, BIOA: 3-Year RORE % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Collegium Pharmaceutical's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Collegium Pharmaceutical 3-Year RORE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Collegium Pharmaceutical's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Collegium Pharmaceutical's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
Collegium Pharmaceutical (FRA:354) has a 3-Year RORE % of -9.30 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Collegium Pharmaceutical and its competitors. According to the industry distribution chart, Collegium Pharmaceutical ranks #542 out of 938 companies in the Drug Manufacturers industry, placing it in the top 57.8%.
Is Collegium Pharmaceutical's 3-Year RORE % too high?
Collegium Pharmaceutical's current 3-Year RORE % is -9.30. Based on the distribution chart, Collegium Pharmaceutical ranks #542 out of 938 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Collegium Pharmaceutical has a GF Score™ of 76/100, reflecting its overall financial health beyond just this single metric.
How does Collegium Pharmaceutical's 3-Year RORE % compare to ALVO and PAHC?
According to the Drug Manufacturers industry distribution chart, Collegium Pharmaceutical ranks #542 out of 938 companies for 3-Year RORE %. This places Collegium Pharmaceutical in the lower half of its industry. The industry median 3-Year RORE % is 3.09. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Drug Manufacturers company?
The median 3-Year RORE % among Drug Manufacturers companies is 3.09, based on 938 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Collegium Pharmaceutical and its competitors. For the Drug Manufacturers industry, the median 3-Year RORE % is 3.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Collegium Pharmaceutical's current 3-Year RORE % is -9.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Collegium Pharmaceutical stock overvalued right now?
Collegium Pharmaceutical (FRA:354) has a current 3-Year RORE % of -9.30. The stock's GF Value™ is €36.92, compared to a current price of €31.00 — trading 16% below its estimated fair value. The current 3-Year RORE % is -9.30. Collegium Pharmaceutical's overall GF Score™ is 76/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Collegium Pharmaceutical (FRA:354), the current 3-Year RORE % is -9.30 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Collegium Pharmaceutical (FRA:354) Overvalued in 2026?
Based on GuruFocus' analysis, Collegium Pharmaceutical stock appears to be undervalued.
The current stock price of €31.00 is trading 16% below its estimated GF Value™ of €36.92.
Key valuation signals for FRA:354:
3-Year RORE %: -9.30
GF Value™: €36.92 vs. price of €31.00 (16% below fair value)
No single metric tells the full story. See the FRA:354 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.
76GF Score
Get the complete analysis for FRA:354
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:354 has been successfully added to your 
